<SEC-DOCUMENT>0001104659-23-075821.txt : 20230628
<SEC-HEADER>0001104659-23-075821.hdr.sgml : 20230628
<ACCEPTANCE-DATETIME>20230628163010
ACCESSION NUMBER:		0001104659-23-075821
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20230628
DATE AS OF CHANGE:		20230628

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Protalix BioTherapeutics, Inc.
		CENTRAL INDEX KEY:			0001006281
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				650643773
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33357
		FILM NUMBER:		231052602

	BUSINESS ADDRESS:	
		STREET 1:		2 UNIVERSITY PLAZA
		STREET 2:		SUITE 100
		CITY:			HACKENSACK
		STATE:			NJ
		ZIP:			07601
		BUSINESS PHONE:		201-696-9345

	MAIL ADDRESS:	
		STREET 1:		2 UNIVERSITY PLAZA
		STREET 2:		SUITE 100
		CITY:			HACKENSACK
		STATE:			NJ
		ZIP:			07601

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ORTHODONTIX INC
		DATE OF NAME CHANGE:	19980422

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EMBASSY ACQUISITION CORP
		DATE OF NAME CHANGE:	19960124
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>tm2320004d1_defa14a.htm
<DESCRIPTION>DEFA14A
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 13.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 13.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 13.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE 14A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Proxy Statement Pursuant to Section&nbsp;14(a)&nbsp;of
the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">Filed by the Registrant&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">Filed by a Party other than the Registrant&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">Check the appropriate box:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Preliminary Proxy Statement</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Confidential, for Use of the
Commission Only (as permitted by Rule&nbsp;14a-6(e)(2))</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Definitive Proxy Statement</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#120;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Definitive Additional Materials</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Soliciting Material Pursuant to
 &sect;240.14a-12</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Protalix BioTherapeutics,&nbsp;Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-top: black 1pt solid"><B>(Name of Registrant
as Specified In Its Charter)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-top: black 1pt solid"><B>(Name of Person(s)&nbsp;Filing
Proxy Statement, if other than the Registrant)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">Payment of Filing Fee (Check the appropriate
box):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#120;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">No fee required.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Fee paid previously with preliminary
materials.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Fee computed on table in exhibit
required by Item 25(b)&nbsp;per Exchange Act Rules&nbsp;14a6(i)(1)&nbsp;and 0-11</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="tm2320004d1_defa14aimg01.jpg" ALT="" STYLE="height: 67px; width: 225px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="padding-left: 0.125in; width: 54%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Barcode</TD>
    <TD STYLE="width: 40%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 0.125in; border-right: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Shareholder Name</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 0.125in; border-right: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Address 1</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 0.125in; border-right: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Address 2</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 0.125in; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Address 3</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>


<P STYLE="margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 78.9pt; text-align: center"><U>Protalix Biotherapeutics Announces
Adjournment of Annual Meeting of Stockholders</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Protalix Biotherapeutics. (Ticker: PLX)
recently announced that the June 28<SUP>th</SUP>, 2023, Annual Meeting is being adjourned until July 13<SUP>th</SUP>, 2023, to provide
stockholders with additional time to vote on Proposal 5, approval of an amendment to the Company&rsquo;s Certificate of Incorporation
to increase the total number of authorized shares of Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><I><U>Our records indicate your account
is currently unvoted.</U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Board of Directors as well
as leading professional advisory firms ISS and Glass Lewis recommend you FOR Proposal 5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Proposal 5 requires an affirmative
vote of 50% of the outstanding shares for passage. By not responding with your vote, you are essentially opposing this proposal. Therefore,
we urge our stockholders who have not yet executed their vote to please do so. This will help save on further solicitation costs and ensure
that your important vote is represented.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><I>Please vote your shares
of stock now so that your vote can be counted without delay. </I></B>If you have any questions or require assistance in voting your shares,
please contact our proxy solicitor Alliance Advisors toll-free at <B>+1 (855) 200- 7892 </B>or email <FONT STYLE="color: #282828"><B>PLX@AllianceAdvisors.com</B></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">If you wish to vote electronically online you can scan the
QR code below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 78.9pt; text-align: center"><U>Insert QR CODE HERE</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 47.2pt">Sincerely,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 407.35pt 0pt 47.2pt">Gina Balderas</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 407.35pt 0pt 47.2pt">Operations Manager</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="1" STYLE="border: Black 1pt solid; vertical-align: middle; padding-top: 3pt; text-align: center; font-weight: bold; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">IF YOU HAVE RECENTLY VOTED PLEASE ACCEPT
    OUR THANKS AND DISREGARD THIS REQUEST.</FONT></TD></TR>
  </TABLE>


<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>tm2320004d1_defa14aimg01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2320004d1_defa14aimg01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !# .$# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P"7P;:^-/&=
MK=3VWBV[MQ;N$(EGD.<C/:NBE\%_$>S0SVGB\W$JC(C>9_F]OF!'YTGP*_Y!
M.K_]=T_]!->LT ><^ _'NH:EK$WAOQ) (-7A!V.%V^85Y(('&<<Y'!'ZY7Q$
MO==E^(^DZ)I.L7-@MW:QC]W*RH&+R#<0/8#\JK>('BO?CWI*:<=TT/E+<E.?
MF7<S?DF ?I5OQC_R7+PQ_P!<(O\ T9+0!(? 7C_!QXWE)[9FEJC)XE\<?#V^
MA'B7;J>E2N$\],-[G:V =V.S#G!QZU['7(_$X6Q^'NJ_:MN BF//7?N&W'OG
M^M '3V5Y!J%C!>6L@D@G021N.ZD9%><>,/B'?MK7_",>$8?M&IEO+DG #;&[
MJH/&1W)X&#^$?AO6+G0O@2VHY82Q1RK;L?X2TI13^#-G\*L_!SP]%9>&SK<J
M[KS4&;#MR5C5L8_$@D^O'I0!G0?""_U8"Z\3^([F>Y;DI&2^WVW-_04EQ\(=
M1T@&Z\+^([F&X7D1R$IN_P"!+_(C%>MT4 >9>#OB'?\ ]L_\(SXM@^S:FK>7
M'.0%#MV##ID]B.#Q^.QXO\,^)]:U:*YT7Q&^FVRP"-H5=UW.&8EOE]B!^%9/
MQC\/1WGAU-=A79>:>RAG'!:-CC'X,01Z<UU_@[6'U_PAIFI2\RS0XD/JZDJQ
M_$J: /(=5M?&FE>,=.\.2>+;MY[U%=95GDVKN9EY[_PUW&@>#_&.G:Y:W>H^
M+)+RTB8F2 R2$.,$8P>.N*R/&/\ R7+PQ_UPB_\ 1DM>LT 17-Q%:6LUS.X2
M&%&DD8_PJ!DG\J^?(/B!XC3Q#'XBEN;S^QGOF4V_F$QA>"4 Z9"L/QYKT'XQ
M:\;#PU%I%N<W6I/M*KU$:D$_F=H]^:DN_ *CX2C04C!OH8OM((ZFX'S$>_4I
M],4 >@12QSPI-$X>.10RL.A!Y!I]>??"'Q!_:_A(6$SYN=-80G/4QGE#^A7_
M (#7H- 'EOPLUK5-4\0>(8;^_N;F.%AY2RR%@GSL.,].@KU*O'O@[_R,WB?_
M 'E_]#>O8: .(^*NHWNE^"VN;"ZFMI_M$:^9$Y5L'.1D5I>'DN-;^'^F>?>W
M*7,]HC&Y20B3=CJ3GG^M8GQD_P"1!?\ Z^H_ZUT'@7_D1-$_Z\X_Y4 <UI^O
MZGX6UE].U^26>V<Y69V+D#LP)Y*^H[?H;OBFUU:S*ZYH^IW4EKQ(\(F9D4==
MP&<%?;M].G2:[H=MKVGFVG^5UYBE Y1O\/45Q>BZU>>$]0.BZTI-F3\C]0@/
M<>JGT[?F* .M\-^(H/$%CO&([J/B6+/0^H]C6W7G7B'09_#UXNOZ$Q6$'<Z)
MR$![^Z']/Y=#8^,]-N-";49Y!$\6%EA!RV[L%'?/;_ZQH UM6U:UT:Q>[NWP
MHX51]YSZ"N+T4ZYXLU9]0EO+FSTU6QLAE9 V/X1@\^YJK:6FH>/=7^V7FZ#3
M83A0.@']U?4GN?\ ZPKTBW@BM;>.""-8XHU"JJ] * #R5]9/^_C?XT5)10!\
MZ?#_ /X3?['>_P#")^5Y/F+Y^_R_O8X^_P"WI78M9?%_4(VMY;VVM$?@R!HE
M('U0$C\.:7X%?\@G5_\ KNG_ *":]9H XCP-\/(?"DDM_=W/VW59P0\V#M0'
MDA<\DD]2?TYSSOC'_DN7AC_KA%_Z,EKUFO)O&/\ R7+PQ_UPB_\ 1DM &MXZ
M^(.K>#=26'^Q89[29<P7)E(!/<$8Z@]L]"*YIM(\:_$Z>TEU98]-T/B5 A #
M CJJY)9B.A/ SQZ5ZCXE\/6?B?0Y],O!@.,QR <QN.C#_/(R*\V^'OB*[\*:
M[+X)\0$H!)MM)&/RJQY"@_W6SD>Y]^ #IOB%HL5M\*[O3["(K%9QQ&-!S\J,
MN<_ADYJU\+KZ*]^'VFB-@6@#0R#^ZP8_T(/XUULT,=Q!)!,@>*12CHW1E(P0
M:\5@EU+X/^)I8YH9+KPY?/E67DCT/H' ZCN/T /;:*R='\3Z+KT"RZ=J-O-N
M'^KW@.OL5/(INL>*=#T&%Y-1U*WA*_\ +/>&D/L%')H Q?BG?16/P^U$.1ON
M-D$8/=BP/\@Q_"I/AC:R6GPZTA) 0SH\F"3T9V8?H17 2R:E\8/$\*QPRVOA
MRQ?YF;@GUYZ%R. .=H_7VJ&&.W@C@A0)%&H1$7HJ@8 % 'E/C'_DN7AC_KA%
M_P"C):]9KR;QC_R7+PQ_UPB_]&2UUOQ&\0_\([X-NYXWVW5P/L\&.H9@<G\!
MD_4"@#R/7_&5G>?%(:S=0O=Z?I\FRWB1@-VS.TY/8O\ -^E=?_PO73_^@)=?
M]_E_PKH/A1X>_L/P=%<2IBZU BX?/4(1\@_+G_@1KN: /G?P=XLM=.^)SWMM
M$UKIFI2F*2)R/W8<Y'M@/C\*^B*\\^,'A_\ M;PG_:$*9N=-;S>!R8SPX_#A
MO^ FMWP#XA_X27PA9WCONN8QY%QGKYB]2?J,'\: .$^#O_(S>)_]Y?\ T-Z]
MAKQ[X._\C-XG_P!Y?_0WKV&@#S_XR?\ (@O_ -?4?]:Z#P+_ ,B)HG_7G'_*
MN?\ C)_R(+_]?4?]:Z#P+_R(FB?]><?\J .@K@?B%J-A-'%IJ1"?4%<$,O6(
M'MQU)XX_^M6GXN\5KI$1L;)M^H2#''/E ]S[^@_'ZT?#V@PZ#9R:_KK8N<%P
M)#DQY_FY_P \T :&AK+X;\)M)KD_[L#(A89**>B>Y/I7FUS:2WHN]4L]/:+3
MTEP0O*QYZ#/^<9'M72J-0^(&L$L6M]+MVZ#^$?U8_I_/T2UL+6SL5LH(46W5
M=NS&01WSZYH SO"^IZ?J.C1+IZ+"(5"/ .L9_J#SSW^N:VJ\VUO1[SPAJBZQ
MH^[[&3\Z=0F>JM_LGL>WUQ7;Z)K=KKM@+FV;##B2(GYHV]#_ $- &E1110!S
M7@_P99^#;:Z@M+F>=;AP[&;'&!CC KI:\D\%Z)X@\3>&H=7/C35K>:1G4)N\
MQ1AB.A/-=3X)UO5KC4=8\/Z[+'/?Z6Z8N8UVB9&&02!P#T_/VH [*N:U3P99
MZKXOT_Q'+<SI<62*B1+C8VUF//&?XC3?"+7C77B#[5J<=ZHU.40JDQD\A,\1
MG^Z1Z5I:MXET30W5-3U.VMI&&51W^8CUVCG'O0!JUROB[P'I?C!K>6ZDEM[F
M#A9H,;BO]TY'3/(_'UK=TS6-.UFW^T:;>P740X+1.&VGT(['ZUQ?Q"\6VUA_
M9EI9:RD%W%JD(NXXIMK+#ABVX#^'[N?PH [FQMY+2Q@MY;F2Z>- IFEQN?'<
MX[TMW9VU_:R6MY!'/!(,/'(H96'T-<3X]\2QR_#V\U+P_JH)CGCC^T6LO*G<
MN1D>Q'YUOW7C7PU97K6=SK=G'.IVLIDSM/H2.!^- ',ZC\&/#%Y*TEL]Y9$_
MP12AD'X,"?UHT[X,^&+.59+AKR](.=DT@5#^"@']:]"CDCFB66)U>-P&5U.0
MP/<&L[5O$6CZ$%_M34K>U+\JLC_,P]0O7'O0!=M+2VL+6.VM((X((QA(XU"J
MH]@*FJAI>MZ7K<+3:9?P72+PWE."5^HZC\:=>:QING3QP7M];V\DJLZ++(%R
MJC+'GL!R: ,?5/!EGJOB_3_$<MS.EQ9(J)$N-C;68\\9_B-,\5^"+/Q?<V4E
M_>7*0VA)$$> KDD9SQGD "MW3M3LM7LUN]/N4N+=B5$B'()!P:RKGQQX7M+L
MVLVN62R@X($F0#Z$C@4 ;ZJ%4*H 4#  Z"EJE%K&FW%W%:0WUO+/+#Y\:)(&
M+QYQN&.HR.M12>(-'A6[:74[6,6;!+@O*!Y3'H#GH3@\4 7YH8[B"2&9 \4B
ME'4]&!&"*YKPAX)M?!OVM;*^NIH;DJ3'-MPI&>1@#L?T%7=-\8>'=7N1;6&L
M6LTY^[&'PS?0'&?PK;H \QN/@GHUS<RSMJ=^&D<N0-G&3GTJ/_A1NB_]!74/
M_'/\*[6^\9^&]-NS:W>M6<<ZG#)YF2I]#CI^-;%M<P7ENEQ:S1S02#*21L&5
MA[$4 <D_PYT]_!4?A<WEU]F2;SA+\N_.2<=,=ZZ'3M*&E:!;Z5:W#@6\ ACF
M=06&!@''3-3VNHV=]+<16MS%-);/Y<RHV3&WH?0TM[J-GIRQ->7,4"S2B&,R
M-C<YZ*/<X- &%I'@RTTW4FU">XDO+C.Y6E'W6[M[FIM?\,'Q!-&9]1EC@C^[
M"B#&>Y]S7/\ Q-\4PZ;H_P!DL=76WU-+B(O'%+MD"'DYQSC&*T_$.N6NK^#-
M4ET'7;6.6((/M2W&U8B6'5ATR,C\: .DL+"VTRSCM+2,1Q(. ._N?4U9JKI[
M,NDVKS3+(P@0O+NR&.T9;/IWS60WCOPJMU]F.O6(DW;?]:-N?][I^M &_)&D
ML;1R(KHP*LK#((]#7-:?X-BTG6#?6%]-"A;F#;E2I_A)SR*Z5)$DC62-U>-A
MN5E.01Z@USS>/O"BWWV,ZY:"8-M^\=F?]_&W]: .CHJ/SX?^>J?]]"B@#R'X
M?V'C*Y\$P-HFLV%I:EY-B2V^YP=QSS@]ZUOAX)]!\4:OH6N1%M<NO]+-[YF]
M;F,<#&<8P23^?3%5?!NJ^(O"WAB'2G\&ZG<21N[;U8*#N8GWK;\.:1K>J>,9
MO%FOV:6!6W^S6=F'#LB9R2Q'U/Y]!@4 4_"E\VF67Q U!5#-:ZG>3!3W*@MC
M]*M> ?"]C-H<.O:I#'?ZKJ0-Q+<7"ARH;HJ@]!C'3^6!5CPCHD\9\6P:G:.E
MO?ZI<,@?CS8GR,CV(-9NE77B+P%"=&N=%O-9TJ%C]CN[%=\@0G.UDZ\9_P#U
MCH 'BS3;;P=K>D^)='C6T\Z\2TO;>(;4FC?/.T<9&#^.#VJ3XGZ;8"#1+@65
MMY\VM6Z2R>4NZ12'R&.,D<#@^E.CL]<\;^(-/O=5TV32M$TZ47$5M.<RW$H^
MZ67L![^_7/&E\0=-O=3LM$2RMI)VAU>":0(,[4 ?+'V&10!F_%*QM+#X;7L5
ME:P6T9GB8I#&$!.X#.!WX'Y5T&G>"M L=$CTQM+M)D$865Y(E9I&QRQ)&<Y_
M+M5'XFZ;>ZMX(NK2PMI+BX:2,K'&,D@,":Z^@#SSP'<-HD7BK2=SRVFC73M;
MJS9(C(9@N?\ @/YDURWA+Q!X>$<VL^(+"\U+6KR1GDF:R,J1KG"JF>  !V^G
M05W/A72+JW\3>+Y;VT=+:]N4,1<?+*N&!Q[<UEZ8=?\ A[YFE?V/=ZSH?F,]
MI-9C?-"I.2C)WY[\=3]  <[K&NZ-#K>G:WX6TV_L]0CG"7,:V;1QW$)^\& X
MS[_X"N@\=Z/;:]\1?">FW@+6TJSM(H.-P5=VWCUVX_&KUO<>*/%NM6<IL[S0
M-$M7\R02OLGNF'12!RJ^H_GQBYK>FWMQ\2?"]_%;2/:6T=R)I0/E0M&0,_4T
M 4/'@_L[1M(\-:,J:?'JMXEH6@4*$C)^;&.YR/KSZUT=CX/\/:?IZV,.CV;0
MA=K>9"KL_NQ(R34'C/PY)XDT58;6<6^H6LRW-I,>BR+TS['/\CVK&B\;^(+6
M$6VH^"M5?4%&TM:*'@<^N_\ A!_&@#'T3P[;^&OC,;2S9OLDNF//#$S$^4K/
M@J,]MP8_C46@>&+/7_B3XHN=27S[6SNU*6K\H\C9PS#H< 'KZU=\/:7XGD^)
MIUW7+/R4N+!@%C;<EO\ -A8BW=L#<<?WJRM-GU_3?'_BO4]'LAJ%LETL=W9!
M]KL#DJZ>I&#Q_M=/0 [KQ%X'T;7-*D@2QM[:Z52;>XAC"-$XZ'([9ZBN-O/&
M>HR?!:UU 2NNH7+BQ>X'WA\S N.^2J_7)K8U#Q+XE\0VLFF:)X8U"PDG4QR7
MFHKY2P@\$@=SZ8_(UI77@.UE^'\?A>*<H84#17!'(E!W;\>Y)X]#0!S&D:YX
M$T?3$LH]!O9@%Q)+/IF]Y3W+$]<^G2CP5J=K:^/9[#0[>^BT._A,OD3PLBP3
MKR=N>Q _4#L*U[;QAXFTNV%EK/A'4KN^C&P7%@OF13$?Q$C[N?\ ('2M+PO;
M>([K4[O6]?=[1)U"6NEI+N2%?[S8X+'^IZ=  4/ '_(Q>,_^PJW_ +-3OB?_
M ,@_P]_V'+;^3U6N(=9\&>+]4U2RTB?5=)U8K)*EKS-#* ?X>X.3^8].<GQ'
M-XG\87^C30>';VRTNTOXG9+@;97;/WRO95 (_P"!?D :GQ;T^R_X1@7GV2W^
MU-=PJTWEC>1G&"V,XJ]\0M/LM/\ AOK2V5G;VRND980Q*@)\Q>N!4OQ+TR]U
M;PJEM86TEQ,+N)]B#)P"<FKGQ L;K4O VJ6=E \]Q*B!(T&2V'4_R% '-^(F
MGU9/!_A-)GAMM3B$EVZ'!:*.,,4!]^?R%=@GA+P['I_V%=%L?LVW;L,"D_7)
MYS[YS6%X@\+W^I:%H=YICK!KFD(DD D^ZQV@-&WUP/Y=\U&/'6N)%Y,O@;6#
MJ &"J+F$M_UTZ8_.@"Y9>#9](\-:UHUAJDK6]W'(+*.4?\>I8$;0V22,D=N.
M3U-8NCZ[HNFZ/:>%O%.B_P!E.B+$1<PAK:=@,%PXXR>N3^==#H,/BBVT74+W
M5Y([G59PTEO8JP$4) .V,-[G@G)[<]ZP];UW5O$.A76BGP3J2WMRAB_T@+]G
MC)&-_F9YQU' Z=: .V_L_3_^>,7YT5Y+_P *=U[_ *&"+_OI_P#"B@#V>BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ KA/ __ ".?C;_K]C_DU%% '=T4
=44 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
